Display options
Cite
Radu MR, Prădatu A, Duică F, et al. Ovarian Cancer: Biomarkers and Targeted Therapy. Biomedicines. 2021;9(6)doi: 10.3390/biomedicines9060693.
Radu, M. R., Prădatu, A., Duică, F., Micu, R., Creţoiu, S. M., Suciu, N., Creţoiu, D., Varlas, V. N., & Rădoi, V. E. (2021). Ovarian Cancer: Biomarkers and Targeted Therapy. Biomedicines, 9(6), . https://doi.org/10.3390/biomedicines9060693
Radu, Mihaela Raluca, et al. "Ovarian Cancer: Biomarkers and Targeted Therapy." Biomedicines vol. 9,6 (2021). doi: https://doi.org/10.3390/biomedicines9060693
Radu MR, Prădatu A, Duică F, Micu R, Creţoiu SM, Suciu N, Creţoiu D, Varlas VN, Rădoi VE. Ovarian Cancer: Biomarkers and Targeted Therapy. Biomedicines. 2021 Jun 18;9(6). doi: 10.3390/biomedicines9060693. PMID: 34207450; PMCID: PMC8235073.
Copy Download .nbib Format: NLM
Share it on

Biomedicines. 2021 Jun 18;9(6). doi: 10.3390/biomedicines9060693.

Ovarian Cancer: Biomarkers and Targeted Therapy.

Biomedicines

Mihaela Raluca Radu, Alina Prădatu, Florentina Duică, Romeo Micu, Sanda Maria Creţoiu, Nicolae Suciu, Dragoş Creţoiu, Valentin Nicolae Varlas, Viorica Elena Rădoi

Affiliations

  1. Fetal Medicine Excellence Research Center, Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania.
  2. Department of Mother and Child, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
  3. Department of Cell and Molecular Biology and Histology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  4. Division of Obstetrics, Gynecology and Neonatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  5. Department of Obstetrics and Gynecology, Alessandrescu-Rusescu National Institute for Mother and Child Health, Polizu Clinical Hospital, 020395 Bucharest, Romania.
  6. Department of Obstetrics and Gynecology, Filantropia Clinical Hospital, 01171 Bucharest, Romania.
  7. Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania.
  8. Department of Medical Genetics, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.

PMID: 34207450 PMCID: PMC8235073 DOI: 10.3390/biomedicines9060693

Abstract

Ovarian cancer is one of the most common causes of death in women as survival is highly dependent on the stage of the disease. Ovarian cancer is typically diagnosed in the late stage due to the fact that in the early phases is mostly asymptomatic. Genomic instability is one of the hallmarks of ovarian cancer. While ovarian cancer is stratified into different clinical subtypes, there still exists extensive genetic and progressive diversity within each subtype. Early detection of the disorder is one of the most important steps that facilitate a favorable prognosis and a good response to medical therapy for the patients. In targeted therapies, individual patients are treated by agents targeting the changes in tumor cells that help them grow, divide and spread. Currently, in gynecological malignancies, potential therapeutic targets include tumor-intrinsic signaling pathways, angiogenesis, homologous-recombination deficiency, hormone receptors, and immunologic factors. Ovarian cancer is usually diagnosed in the final stages, partially due to the absence of an effective screening strategy, although, over the times, numerous biomarkers have been studied and used to assess the status, progression, and efficacy of the drug therapy in this type of disorder.

Keywords: NTRK inhibitors; PARP inhibitors; biomarkers; ncRNAs; ovarian cancer; targeted therapy

References

  1. BMC Cancer. 2012 Dec 28;12:627 - PubMed
  2. Pathology. 2018 Feb;50(2):178-189 - PubMed
  3. Gynecol Oncol. 2004 Oct;95(1):62-9 - PubMed
  4. J Pathol Clin Res. 2016 Jul 13;2(4):247-258 - PubMed
  5. Ginekol Pol. 2017;88(10):543-551 - PubMed
  6. J Ovarian Res. 2019 Mar 18;12(1):23 - PubMed
  7. Oncol Lett. 2020 Jul;20(1):373-381 - PubMed
  8. PLoS One. 2016 May 26;11(5):e0155250 - PubMed
  9. Arch Gynecol Obstet. 2014 Nov;290(5):839-42 - PubMed
  10. Cell Physiol Biochem. 2018;49(4):1289-1303 - PubMed
  11. Signal Transduct Target Ther. 2020 Jul 29;5(1):137 - PubMed
  12. Urol Clin North Am. 2016 Feb;43(1):127-34 - PubMed
  13. J Exp Clin Cancer Res. 2017 Nov 2;36(1):153 - PubMed
  14. Curr Oncol Rep. 2014 Jun;16(6):389 - PubMed
  15. Med Sci Monit. 2019 Dec 24;25:9902-9912 - PubMed
  16. Nat Rev Mol Cell Biol. 2016 Apr;17(4):205-11 - PubMed
  17. Front Endocrinol (Lausanne). 2017 Apr 07;8:66 - PubMed
  18. Wiley Interdiscip Rev RNA. 2017 Nov;8(6): - PubMed
  19. Diagnostics (Basel). 2021 Jan 29;11(2): - PubMed
  20. Gynecol Oncol. 2015 May;137(2):343-50 - PubMed
  21. Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1062-1071 - PubMed
  22. Nature. 2011 Jun 29;474(7353):609-15 - PubMed
  23. Carcinogenesis. 2005 Oct;26(10):1651-6 - PubMed
  24. JAMA. 2012 Jan 25;307(4):382-90 - PubMed
  25. Int Immunopharmacol. 2020 Jul;84:106471 - PubMed
  26. Am J Transl Res. 2020 Nov 15;12(11):6977-6987 - PubMed
  27. Clin Chim Acta. 2015 Jun 15;446:147-55 - PubMed
  28. Life Sci. 2020 Aug 1;254:117176 - PubMed
  29. JCO Precis Oncol. 2017;2017: - PubMed
  30. Oncotarget. 2017 Sep 6;8(52):89811-89823 - PubMed
  31. Cancers (Basel). 2017 Aug 09;9(8): - PubMed
  32. JAMA. 2017 Jun 20;317(23):2402-2416 - PubMed
  33. Gynecol Oncol. 2013 Dec;131(3):772-9 - PubMed
  34. Cancer. 2003 May 15;97(10 Suppl):2631-42 - PubMed
  35. Elife. 2017 Oct 31;6: - PubMed
  36. J Pathol. 2001 Nov;195(4):451-6 - PubMed
  37. Br J Cancer. 2018 Jul;119(2):141-152 - PubMed
  38. J Cancer. 2018 Apr 24;9(10):1846-1855 - PubMed
  39. Zoolog Sci. 2020 Apr;37(2):103-108 - PubMed
  40. Ann Oncol. 2017 Nov 1;28(suppl_8):viii8-viii12 - PubMed
  41. Oncotarget. 2017 Sep 8;8(56):95377-95391 - PubMed
  42. Curr Genet. 2018 Oct;64(5):985-996 - PubMed
  43. Pharmacol Ther. 2018 Sep;189:45-62 - PubMed
  44. Nat Rev Dis Primers. 2016 Aug 25;2:16061 - PubMed
  45. Int Rev Cell Mol Biol. 2017;330:295-342 - PubMed
  46. Cancer Res. 2019 Aug 15;79(16):3995-4002 - PubMed
  47. Gynecol Oncol. 2014 Feb;132(2):506-12 - PubMed
  48. Hum Pathol. 2011 Jul;42(7):918-31 - PubMed
  49. Mol Cancer. 2019 Oct 17;18(1):144 - PubMed
  50. Genet Test Mol Biomarkers. 2020 Mar;24(3):145-149 - PubMed
  51. Semin Oncol Nurs. 2019 Apr;35(2):151-156 - PubMed
  52. BMC Womens Health. 2014 Dec 12;14:150 - PubMed
  53. Cell Cycle. 2014;13(1):78-89 - PubMed
  54. Cell Rep. 2019 Dec 10;29(11):3448-3459.e6 - PubMed
  55. Nat Genet. 1998 Aug;19(4):348-55 - PubMed
  56. Crit Rev Eukaryot Gene Expr. 2019;29(2):161-170 - PubMed
  57. Ann Transl Med. 2017 Jul;5(13):276 - PubMed
  58. Annu Rev Pathol. 2009;4:287-313 - PubMed
  59. J Biol Chem. 2019 Jul 19;294(29):11062-11086 - PubMed
  60. J Ovarian Res. 2016 Apr 06;9:21 - PubMed
  61. Cancers (Basel). 2019 Mar 08;11(3): - PubMed
  62. Cell Death Differ. 2014 Aug;21(8):1275-89 - PubMed
  63. Cell Signal. 2014 Jul;26(7):1420-6 - PubMed
  64. Cancer Res. 2005 Jun 1;65(11):4939-46 - PubMed
  65. Cancers (Basel). 2021 Mar 17;13(6): - PubMed
  66. Crit Rev Eukaryot Gene Expr. 2014;24(1):15-28 - PubMed
  67. Vasc Health Risk Manag. 2006;2(3):213-9 - PubMed
  68. Ann Transl Med. 2020 Sep;8(17):1092 - PubMed
  69. J Ovarian Res. 2019 Mar 27;12(1):28 - PubMed
  70. J Cancer. 2016 May 20;7(8):991-1001 - PubMed
  71. Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4656-4662 - PubMed
  72. Semin Cancer Biol. 2018 Dec;53:265-281 - PubMed
  73. Nat Rev Cancer. 2011 Sep 23;11(10):719-25 - PubMed
  74. Sci Rep. 2018 Jul 9;8(1):10306 - PubMed
  75. Int J Mol Sci. 2020 Sep 25;21(19): - PubMed
  76. Mol Biol (Mosk). 2018 Nov-Dec;52(6):907-920 - PubMed
  77. Acta Pharmacol Sin. 2012 Mar;33(3):351-62 - PubMed
  78. Front Genet. 2020 Mar 17;11:219 - PubMed
  79. ESMO Open. 2016 Mar 18;1(2):e000023 - PubMed
  80. Development. 2017 Jul 15;144(14):2548-2559 - PubMed
  81. Ther Adv Med Oncol. 2019 May 22;11:1758835919849753 - PubMed
  82. Cell. 2011 Aug 5;146(3):353-8 - PubMed
  83. Hematol Oncol Clin North Am. 2018 Dec;32(6):903-914 - PubMed
  84. J Clin Oncol. 2008 Jan 1;26(1):20-5 - PubMed
  85. Am J Pathol. 2016 Apr;186(4):733-47 - PubMed
  86. Gynecol Oncol. 2003 Aug;90(2):378-81 - PubMed
  87. Nature. 1991 Mar 14;350(6314):158-60 - PubMed
  88. Mol Med Rep. 2016 Sep;14(3):2465-72 - PubMed
  89. Diagnostics (Basel). 2021 Apr 14;11(4): - PubMed
  90. Cancer Discov. 2018 Mar;8(3):304-319 - PubMed
  91. Mol Cancer. 2016 Jun 24;15(1):48 - PubMed
  92. Cancer Cell. 2019 Apr 15;35(4):588-602.e10 - PubMed
  93. J Clin Oncol. 2007 Nov 20;25(33):5180-6 - PubMed
  94. Arch Gynecol Obstet. 2016 Apr;293(4):695-700 - PubMed
  95. Mol Cancer Res. 2012 Mar;10(3):469-82 - PubMed
  96. Cancer Discov. 2015 Jan;5(1):25-34 - PubMed
  97. Nat Rev Cancer. 2019 Sep;19(9):522-537 - PubMed
  98. Cell. 2000 Feb 18;100(4):387-90 - PubMed
  99. Int J Gynecol Pathol. 2000 Jan;19(1):7-15 - PubMed
  100. Clin Cancer Res. 2012 Aug 15;18(16):4313-24 - PubMed
  101. J Cell Physiol. 2019 Nov;234(11):19886-19894 - PubMed
  102. Epigenomics. 2020 Jul;12(14):1175-1191 - PubMed
  103. J Cell Physiol. 2018 May;233(5):3846-3854 - PubMed
  104. J Ovarian Res. 2020 Jul 1;13(1):75 - PubMed
  105. Cancer Res. 2011 Oct 1;71(19):6184-94 - PubMed
  106. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2285-95 - PubMed
  107. Drug Discov Today. 2018 Sep;23(9):1635-1643 - PubMed
  108. Gene. 2016 Feb 1;576(2 Pt 2):791-7 - PubMed
  109. J Ovarian Res. 2021 Mar 18;14(1):47 - PubMed
  110. Oncogene. 2010 Feb 25;29(8):1103-13 - PubMed
  111. J Cancer. 2020 Aug 27;11(21):6226-6233 - PubMed
  112. Adv Anat Pathol. 2009 Sep;16(5):267-82 - PubMed
  113. J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 - PubMed
  114. J Pathol. 2017 Sep;243(1):26-36 - PubMed
  115. Cells. 2020 Nov 28;9(12): - PubMed
  116. Cancer Manag Res. 2020 Jul 07;12:5479-5489 - PubMed
  117. Expert Rev Anticancer Ther. 2017 Sep;17(9):827-839 - PubMed
  118. Br J Radiol. 2012 May;85(1013):477-86 - PubMed
  119. Int J Mol Sci. 2020 Nov 23;21(22): - PubMed
  120. Clin Chem Lab Med. 2017 May 1;55(5):715-736 - PubMed
  121. J Pers Med. 2021 Apr 19;11(4): - PubMed
  122. Gynecol Oncol. 2006 Sep;102(3):429-31 - PubMed
  123. Semin Cancer Biol. 2019 Oct;58:29-46 - PubMed
  124. Ginekol Pol. 2017;88(12):692-697 - PubMed
  125. Nat Rev Cancer. 2011 Dec 23;12(1):68-78 - PubMed
  126. J Exp Clin Cancer Res. 2018 Sep 24;37(1):237 - PubMed
  127. Crit Rev Oncol Hematol. 2017 Dec;120:43-51 - PubMed
  128. Nat Commun. 2019 Oct 31;10(1):4965 - PubMed
  129. J Clin Oncol. 1998 Feb;16(2):397-404 - PubMed
  130. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747 - PubMed
  131. Nat Rev Cancer. 2019 Feb;19(2):97-109 - PubMed
  132. Am J Pathol. 2004 Aug;165(2):397-414 - PubMed
  133. J Pathol. 2007 Jan;211(1):26-35 - PubMed
  134. Int J Clin Exp Pathol. 2015 Sep 01;8(9):10082-91 - PubMed
  135. J Cancer. 2020 Jan 1;11(3):599-609 - PubMed
  136. Carcinogenesis. 2012 Jan;33(1):20-9 - PubMed
  137. Aging (Albany NY). 2019 Dec 3;11(23):11416-11439 - PubMed
  138. Nat Rev Mol Cell Biol. 2018 Sep;19(9):547-562 - PubMed
  139. Semin Cancer Biol. 2015 Dec;35 Suppl:S199-S223 - PubMed
  140. Onco Targets Ther. 2017 Jun 01;10:2805-2813 - PubMed
  141. J Ovarian Res. 2019 Dec 9;12(1):121 - PubMed
  142. Mod Pathol. 2012 Apr;25(4):625-36 - PubMed
  143. Nature. 2013 May 2;497(7447):67-73 - PubMed
  144. Onco Targets Ther. 2019 Aug 16;12:6371-6383 - PubMed
  145. BMC Cancer. 2009 Oct 23;9:378 - PubMed
  146. Lancet Oncol. 2017 Sep;18(9):1274-1284 - PubMed
  147. Br J Cancer. 2018 Oct;119(7):864-872 - PubMed
  148. Cancer Res. 1999 Feb 15;59(4):868-71 - PubMed
  149. Cancer Biol Ther. 2007 Nov;6(11):1733-42 - PubMed
  150. Cell Death Differ. 2015 Aug;22(8):1239-49 - PubMed
  151. Front Genet. 2019 Aug 21;10:751 - PubMed
  152. Onco Targets Ther. 2017 May 23;10:2701-2709 - PubMed
  153. Front Mol Biosci. 2017 Jun 06;4:38 - PubMed
  154. Mol Med Rep. 2017 Sep;16(3):3379-3386 - PubMed
  155. Biomed Rep. 2016 Jul;5(1):41-44 - PubMed
  156. Hum Pathol. 2018 Oct;80:11-27 - PubMed
  157. Expert Rev Mol Diagn. 2017 Jun;17(6):577-591 - PubMed

Publication Types

Grant support